Log in

NASDAQ:VICLVical Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.01
-0.02 (-1.94 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.00
Now: $1.01
$1.03
50-Day Range
$0.68
MA: $1.24
$3.15
52-Week Range
$0.60
Now: $1.01
$1.47
Volume807,990 shs
Average Volume1.44 million shs
Market Capitalization$23.07 million
P/E RatioN/A
Dividend YieldN/A
Beta0.32
Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.
Read More
Vical logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.81 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VICL
CUSIP92560210
Phone858-646-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.62 million
Book Value$1.82 per share

Profitability

Net Income$-16,250,000.00
Net Margins-1,002.10%

Miscellaneous

Employees30
Market Cap$23.07 million
Next Earnings DateN/A
OptionableOptionable

Receive VICL News and Ratings via Email

Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter.

Vical (NASDAQ:VICL) Frequently Asked Questions

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) posted its quarterly earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.17). The biotechnology company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.04 million. Vical had a negative return on equity of 29.46% and a negative net margin of 1,002.10%. View Vical's earnings history.

Has Vical been receiving favorable news coverage?

Media headlines about VICL stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Vical earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Vical.

Who are some of Vical's key competitors?

What other stocks do shareholders of Vical own?

Who are Vical's key executives?

Vical's management team includes the following people:
  • Mr. Vijay B. Samant, CEO, Pres & Director (Age 66)
  • Dr. Lawrence Russell Smith, Sr. VP of Research (Age 58)
  • Mr. Anthony Alan Ramos, VP, CFO & Chief Accounting Officer (Age 52)
  • Dr. Mammen P. Mammen Jr., Former Sr. VP of Clinical Devel. (Age 55)

What is Vical's stock symbol?

Vical trades on the NASDAQ under the ticker symbol "VICL."

What is Vical's stock price today?

One share of VICL stock can currently be purchased for approximately $1.01.

How big of a company is Vical?

Vical has a market capitalization of $23.07 million and generates $1.62 million in revenue each year. The biotechnology company earns $-16,250,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Vical employs 30 workers across the globe.

What is Vical's official website?

The official website for Vical is www.vical.com.

How can I contact Vical?

Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.